Literature DB >> 8097684

Somatostatin as a modulator of distal nephron water permeability.

C Ray1, S Carney, T Morgan, A Gillies.   

Abstract

1. Experiments in vivo and in vitro were performed in the rat to define the role of somatostatin in modulating the hydro-osmotic action of arginine vasopressin. 2. Somatostatin had a biphasic effect on basal collecting duct diffusional water permeability with 10(-9) mol/l somatostatin producing a 14% reduction in permeability, whereas concentrations of 10(-6) and 10(-5) mol/l significantly increased basal water permeability by 13% and 22%, respectively. Somatostatin (10(-9) mol/l) also inhibited the increase in water permeability produced by arginine vasopressin, although this inhibitory effect was reduced by a 10-fold increase in arginine vasopressin concentration (5 ng/ml). 3. In the anaesthetized water-diuretic rat, low dose somatostatin (60 micrograms/h) increased free water clearance by 23% (P < 0.01), whereas increasing the somatostatin concentration (600 micrograms/h) produced a transitory 40% fall in free water clearance (P < 0.01). As in the experiment in vitro, somatostatin inhibited the action of arginine vasopressin, although a very high concentration of arginine vasopressin (250 ng/h) partly overcame this effect. 4. Glomerular filtration rate and renal electrolyte excretion (sodium, potassium, calcium, magnesium) were not altered by somatostatin, although renal inorganic phosphate excretion was increased. The papillary solute gradient was unaltered by somatostatin. 5. These results suggest that circulating somatostatin may have a physiological role in modulating distal nephron water transport with a low concentration directly inhibiting and a high concentration facilitating water transport. There is also evidence of competitive binding between somatostatin and arginine vasopressin which antagonizes the hydro-osmotic action of arginine vasopressin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097684     DOI: 10.1042/cs0840455

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  11 in total

1.  Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.

Authors:  A Lianne Messchendorp; Edwin M Spithoven; Niek F Casteleijn; Wendy A Dam; Jacob van den Born; Wouter F Tonnis; Carlo A J M Gaillard; Esther Meijer
Journal:  BMC Nephrol       Date:  2018-12-19       Impact factor: 2.388

Review 2.  Cyclic AMP-mediated cyst expansion.

Authors:  Darren P Wallace
Journal:  Biochim Biophys Acta       Date:  2010-11-28

Review 3.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

4.  Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.

Authors:  Sunil Bhandari; Neil Watson; Ervine Long; Steve Sharpe; Wenwen Zhong; Shang-Zhong Xu; Stephen L Atkin
Journal:  J Histochem Cytochem       Date:  2008-04-28       Impact factor: 2.479

Review 5.  Vasopressin antagonists in polycystic kidney disease.

Authors:  Vicente E Torres
Journal:  Semin Nephrol       Date:  2008-05       Impact factor: 5.299

Review 6.  Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

Authors:  Caroline R Sussman; Xiaofang Wang; Fouad T Chebib; Vicente E Torres
Journal:  Cell Signal       Date:  2020-04-23       Impact factor: 4.315

Review 7.  Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives.

Authors:  Cristina Hernández; Olga Simó-Servat; Rafael Simó
Journal:  Endocrine       Date:  2014-03-14       Impact factor: 3.633

8.  Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD.

Authors:  A Lianne Messchendorp; Bart J Kramers; Edwin M Spithoven; Katrin Stade; Esther Meijer; Ron T Gansevoort
Journal:  Kidney Int Rep       Date:  2019-05-16

9.  Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.

Authors:  A Lianne Messchendorp; Niek F Casteleijn; Esther Meijer; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2020-08-01       Impact factor: 5.992

10.  Reassessment of SST4 Somatostatin Receptor Expression Using SST4-eGFP Knockin Mice and the Novel Rabbit Monoclonal Anti-Human SST4 Antibody 7H49L61.

Authors:  Amelie Lupp; Blanca Ehms; Ralf Stumm; Johannes Göckeritz; Christian Mawrin; Stefan Schulz
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.